Novel porcine rotavirus

Patent metadata

Field	Value
Publication number	US-2025011730-A1
Application number	US-202418742851-A
Country	US
Kind code	A1
Filing date	Jun 13, 2024
Priority date	Nov 12, 2018
Publication date	Jan 9, 2025
Grant date	—

Abstract

The present invention pertains to a novel rotavirus, especially an isolated virus, which is a member of the sub-species of porcine group B rotavirus (porcine RVB), causing diarrheal disease in pigs, to DNA fragments and corresponding proteins of the said virus, to vaccines on the basis of said virus, DNA and/or protein and to antibodies reactive with said virus and/or protein and diagnostic test kits for the detection of said virus.

First claim

1 . An isolated rotavirus which is a member of the sub-species of porcine group B rotaviruses genotype G12, which in its wild type form causes diarrhea in pigs, said virus being characterized in that it has a viral genome comprising an open reading frame having a nucleotide sequence corresponding to the nucleotide sequence depicted in SEQ ID NO:
1 or a nucleotide sequence having at least 90% sequence identity to SEQ ID NO: 1.

2 . The isolated virus according to claim 1 , characterized in that the nucleotide sequence having a level of identity of at least 90% to the nucleotide sequence depicted in SEQ ID NO: 1 encodes an outer viral capsid glycoprotein VP7.

3 . A nucleic acid fragment comprising an open reading frame, said open reading frame comprising at least 200 nucleotides, characterized in that said nucleic acid fragment has a nucleotide sequence that corresponds to a sequence having a level of identity of at least 90% to the nucleotide sequence depicted in SEQ ID NO: 1.

4 . The nucleic acid fragment according to claim 3 , characterized in that the open reading frame encodes an outer viral capsid glycoprotein VP7.

5 . The nucleic acid fragment according to claim 3 , characterized in that the open reading frame is under the control of a heterologous promoter.

6 . A recombinant protein encoded by the open reading frame of the nucleic acid fragment according to claim 3 .

7 . An outer viral capsid glycoprotein VP7 or a fragment thereof, characterized that it is a protein according to SEQ ID NO:2, or a protein having a level of identity of at least 93% therewith. 8 (Currently Amended) A vaccine for use in protecting against an infection caused by porcine group B rotavirus, characterized in that said vaccine comprises an immunogenically effective amount of a virus according to claim 1 , and a pharmaceutically acceptable carrier.

9 . The vaccine according to claim 8 for use in prophylactically treating an animal.

10 . A vaccine for use in protecting against an infection caused by porcine group B rotavirus, characterized in that said vaccine comprises an immunogenically effective amount of an outer viral capsid glycoprotein VP7 according to claim 7 .

11 . (canceled)

12 . (canceled)

13 . A method for protecting an animal against an infection caused by porcine group B rotavirus by systemically administering a vaccine according to claim 8 to the animal.

14 . (canceled)

15 . A virus according to any one of claim 1 , for use in the manufacture of a vaccine for protecting an animal against an infection caused by porcine group B rotavirus.

16 . The nucleic acid fragment according to claim 4 , wherein the nucleic acid fragment is present in a nucleic acid construct or an expression vector.

17 . The nucleic acid fragment according to claim 16 , wherein the nucleic acid construct is a alphavirus RNA replicon particle.

18 . The nucleic acid fragment according to claim 17 , wherein the alphavirus RNA replicon particle is a Venezuelan Equine Encephalitis (VEE) alphavirus RNA replicon particle.

19 . An alphavirus RNA replicon particle comprising a nucleic acid fragment selected from:
a nucleic acid fragment that encodes an outer viral capsid glycoprotein VP7, a nucleic acid fragment having at least 90% nucleotide sequence identity to SEQ ID NO: 1, or a nucleic acid fragment that encodes a outer viral capsid glycoprotein VP7 having the amino acid sequence of SEQ ID NO:2, or an amino acid sequence having at least 93% sequence identity to SEQ ID NO: 2.

20 . The alphavirus RNA replicon particle of claim 19 , wherein the alphavirus RNA replicon particle is a Venezuelan Equine Encephalitis (VEE) alphavirus RNA replicon particle.

21 . The nucleic acid fragment according to claim 16 , for use in the manufacturer of a vaccine for protecting an animal against an infection caused by a porcine group B rotavirus.

22 . An immunogenic composition comprising the alphavirus RNA replicon of claim 19 and a pharmaceutically acceptable carrier.

23 . A vaccine to aid the prevention of disease due to a porcine group B rotavirus, comprising the nucleic acid fragment of claim 18 and a pharmaceutically acceptable carrier.

Assignees

• Intervet Inc

Inventors

• De Groof Ad
• Vermeij Paul
• Van Der Hoek Cornelia Maria
• Deijs Martin

Classifications

• C12N2720/12334

  Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein · CPC title

• C12N2720/12322

  New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes · CPC title

• C12N2720/12321

  Viruses as such, e.g. new isolates, mutants or their genomic sequences · CPC title

• C07K14/005

  from viruses · CPC title

• C12N7/00 Primary

  Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00) · CPC title